OBLN Obalon Therapeutics

Robbins Arroyo LLP: Obalon Therapeutics, Inc. (OBLN) Misled Shareholders According to a Recently Filed Class Action

Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Obalon Therapeutics, Inc. (NasdaqGM: OBLN) have filed a class action complaint against the company's officers and directors for alleged violations of the Securities Exchange Act of 1934 between October 5, 2016 and January 23, 2018. Obalon develops and commercializes medical devices to treat obese and overweight people by facilitating weight loss.

View this information on the law firm's Shareholder Rights Blog:

www.robbinsarroyo.com/obalon-therapeutics-inc-feb-2018

Obalon Accused of Implementing Inadequate Internal Controls Over Financial Reporting

According to the complaint, Obalon repeatedly attested in its public filings and press releases that its financial statements were prepared in accordance with United States generally accepted accounting principles. Obalon emphasized substantial revenue growth and improvements in its gross margin in its financial reports throughout the class period. It therefore came as a surprise when Obalon revealed on January 23, 2018, that a whistleblower contacted KPMG LLP, the company's independent auditors, to allege that Obalon had improperly recognized revenue during the company's fourth fiscal quarter of 2017. As a result, Obalon canceled its previously announced offering of 5,454,545 shares of its common stock at a price of $5.50 per share and said that its Audit Committee would investigate the allegations. On this news, Obalon's stock fell nearly 77% from its IPO price of $15.00 per share to close at only $3.46 per share on January 23, 2018.

Obalon Shareholders Have Legal Options

If you would like more information about your rights and potential remedies, contact attorney Leonid Kandinov at (800) 350-6003, [email protected], or via the shareholder information form on the firm's website.

Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.

Attorney Advertising. Past results do not guarantee a similar outcome.

EN
19/02/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Obalon Therapeutics

 PRESS RELEASE

Obalon Announces First Quarter 2021 Financial Results

Obalon Announces First Quarter 2021 Financial Results SAN DIEGO, May 12, 2021 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the first quarter ended March 31, 2021. On January 19, 2020 the Company signed a definitive agreement for a merger with ReShape Lifesciences Inc. Financial results for the first quarter of 2021 Revenue for the first quarter of 2021 was no...

 PRESS RELEASE

Obalon Announces Fourth Quarter and Full Year 2020 Financial Results

Obalon Announces Fourth Quarter and Full Year 2020 Financial Results SAN DIEGO, March 12, 2021 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the fourth quarter and full year ended December 31, 2020. On November 10, 2020, the Company signed a non-binding term sheet for merger with ReShape Lifesciences Inc. and, on January 20, 2021, announced that a definitive agreeme...

 PRESS RELEASE

Obalon Announces Third Quarter 2020 Financial Results

Obalon Announces Third Quarter 2020 Financial Results SAN DIEGO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the third quarter ended September 30, 2020. Financial results for the third quarter of 2020 Revenue for the third quarter of 2020 was $44,000, compared to $0.3 million for the third quarter of 2019, with the decrease primarily due to the sus...

 PRESS RELEASE

Obalon Announces Consulting Agreement As Part of Strategy To Seek Cove...

Obalon Announces Consulting Agreement As Part of Strategy To Seek Coverage and Reimbursement for The Obalon Balloon System SAN DIEGO, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (Nasdaq: OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that it has executed a consulting agreement with Blue Ox Healthcare Partners, LLC, a private equity firm focused on commercial-ready companies bringing technology enabled innovation to healthcare, especially those invo...

 PRESS RELEASE

Obalon Announces Second Quarter 2020 Financial Results

Obalon Announces Second Quarter 2020 Financial Results SAN DIEGO, July 30, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the second quarter ended June 30, 2020. Financial results for the second quarter of 2020 Revenue for the second quarter of 2020 was $0.7 million, compared to $0.4 million for the second quarter of 2019, primarily due to reversals of revenue...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch